Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Intranasal placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    154 result(s) found for: Intranasal placebo. Displaying page 7 of 8.
    « Previous 1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2019-002859-42 Sponsor Protocol Number: OPNT002-AUD-001 Start Date*: 2020-01-28
    Sponsor Name:Opiant Pharmaceuticals Inc
    Full Title: Randomised, double-blind, placebo-controlled trial evaluating the effects of naltrexone hydrochloride nasal spray on alcohol consumption in Alcohol Use Disorder
    Medical condition: Alcohol use Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.1 10037175 - Psychiatric disorders 10080021 Alcohol use disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed)
    Trial results: View results
    EudraCT Number: 2014-004916-12 Sponsor Protocol Number: P05106 Start Date*: 2015-02-24
    Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation
    Full Title: Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Treatment of Seasonal Allergic Rhinitis (Protocol No. P05106).
    Medical condition: Seasonal Allergic Rhinitis
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-005740-34 Sponsor Protocol Number: ESR-14-10698 Start Date*: 2017-12-08
    Sponsor Name:Universitätsklinikum Tübingen
    Full Title: Effectiveness of Dapagliflozin + Saxagliptin to revert from a standard basalbolus insulin treatment (BBIT) regimen to a basal supported oral therapy (BOT) in patients with Type 2 Diabetes – a rando...
    Medical condition: Diabetes Melitus Type 2
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10018424 Glucose metabolism disorders (incl diabetes mellitus) HLGT
    20.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004875-21 Sponsor Protocol Number: P05067 Start Date*: 2015-02-24
    Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation
    Full Title: Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Treatment of Seasonal Allergic Rhinitis (Protocol No. P05067)
    Medical condition: Seasonal Allergic Rhinitis
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-003663-35 Sponsor Protocol Number: PBF-680CT-05 Start Date*: 2018-06-13
    Sponsor Name:Palobiofarma S.L
    Full Title: A phase II, double-blind, randomized, parallel-group, placebocontrolled multi-center study to investigate the effect of the adenosine A1 receptor antagonist PBF-680 on forced expiratory volume in 1...
    Medical condition: patients with mild-to-moderate persistent atopic asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10003638 Atopic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004888-37 Sponsor Protocol Number: FFR111158 Start Date*: 2016-08-03
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Pilot, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Evaluate the Efficacy and Safety of Once-daily Intranasal Administration of Fluticasone Furoate Nasal Spr...
    Medical condition: Irritant (non-allergic) rhinitis
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-004493-25 Sponsor Protocol Number: FFR106080 Start Date*: 2006-01-12
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg...
    Medical condition: Perennial Allergic Rhinitis
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) EE (Completed) LV (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005492-25 Sponsor Protocol Number: PrEP-CS-003 Start Date*: 2016-03-10
    Sponsor Name:PrEP Biopharm Ltd.
    Full Title: A phase IIa, randomised, double-blind, placebo-controlled study using outpatient setting to investigate the duration of effect and evaluate further safety of PrEP-001 given prophylactically in heal...
    Medical condition: Human Rhinovirus (HRV-16)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10022891 - Investigations 10075163 Human rhinovirus test PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-004761-33 Sponsor Protocol Number: CRO1881 Start Date*: 2012-03-08
    Sponsor Name:Imperial College
    Full Title: A randomised double-blind placebo-controlled Phase 2B clinical trial of repeated application of gene therapy in patients with cystic fibrosis
    Medical condition: Cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011763 Cystic fibrosis lung PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-006562-15 Sponsor Protocol Number: FFU111439 Start Date*: 2008-03-28
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110m...
    Medical condition: Perennial Allergic Rhinitis (PAR) in adults and children of 12 years and older.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10034382 Perennial allergic rhinitis LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: EE (Completed) HU (Completed) SK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001036-25 Sponsor Protocol Number: UNI91103-201 Start Date*: 2021-06-01
    Sponsor Name:UNION therapeutics A/S
    Full Title: A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF UNI91103 INTRANASAL ADMINISTRATION IN ADULTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC COVID-19
    Medical condition: Covid-19
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-005048-17 Sponsor Protocol Number: VRP080415 Start Date*: 2009-01-27
    Sponsor Name:Verona Pharma Plc
    Full Title: A Combined Clinical Phase I/IIa Study of the Safety and Efficacy of Nebulised RPL554 in Healthy Subjects, Allergic Asthmatics, and Allergic Rhinitics
    Medical condition: Allergic Asthma and Allergic Rhinitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001705 Allergic asthma LLT
    9.1 10001723 Allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005037-16 Sponsor Protocol Number: 217095 Start Date*: 2022-05-17
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A randomised, double-blind, parallel group Phase III study to assess the efficacy and safety of 100 mg SC depemokimab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) – ANCHOR-1 (...
    Medical condition: Chronic Rhinosinusitis with Nasal Polyps
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038738 - Respiratory, thoracic and mediastinal disorders 10080060 Chronic rhinosinusitis with nasal polyps PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) DE (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004255-70 Sponsor Protocol Number: 205687 Start Date*: 2017-05-29
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomised, double-blind, parallel group PhIII study to assess the clinical efficacy and safety of 100 mg SC Mepolizumab as an add on to maintenance treatment in adults with severe bilateral nasa...
    Medical condition: Treatment of nasal polyposis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10028756 Nasal polyps PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) SE (Completed) NL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2010-018740-13 Sponsor Protocol Number: acareoxt01 Start Date*: 2011-08-25
    Sponsor Name:University Medical Center Groningen
    Full Title: Short- and long-term effects of oxytocin on empathy and social behaviour in autistic and antisocial male adults.
    Medical condition: Antisocial personality disorder Autism spectrum disorder
    Disease: Version SOC Term Classification Code Term Level
    12.1 10002822 Antisocial personality disorder LLT
    12.1 10063844 Autism spectrum disorder LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001913-51 Sponsor Protocol Number: RC 15/08 Start Date*: 2009-03-23
    Sponsor Name:ISTITUTO PER L'INFANZIA BURLO GAROFOLO
    Full Title: SYNERGIC EFFECTS OF OXYTOCIN AND PSYCHOTHERAPY IN POSTPARTUM DEPRESSION. RANDOMIZED CONTROLLED STUDY.
    Medical condition: Postpartum depression.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036235 Postnatal blues LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017048-15 Sponsor Protocol Number: 217-2009-10-28 Start Date*: 2010-05-18
    Sponsor Name:Universitätsmedizin Göttingen
    Full Title: Botulinum Neurotoxin Typ A (Xeomin®) als Therapieoption der allergischen und intrinsischen Rhinitis
    Medical condition: Es handelt sich um eine monozentrische, randomisierte, doppelblinde, placebokontrollierte Studie der Phase II, die an 45 Personen mit allergischer oder intrinsischer Rhinitis durchgeführt werden so...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006710-15 Sponsor Protocol Number: IPR109764 Start Date*: 2007-03-23
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A randomised, single blind, placebo-controlled 5-way crossover trial of single doses of intranasal GSK256066 in subjects with seasonal allergic rhinitis (SAR)
    Medical condition: Seasonal Allergic Rhinitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039776 Seasonal allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002895-26 Sponsor Protocol Number: PrEP-CS-001 Start Date*: 2015-09-08
    Sponsor Name:hVIVO Services Limited
    Full Title: A Phase II, Repeated Dose, Double-Blinded, Randomised, Controlled Study to Examine the Prophylactic Efficacy, Safety and Tolerability of PrEP-001 in Healthy Subjects Subsequently Challenged with In...
    Medical condition: Influenza A/Perth/16/2009(H3N2) Virus
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-000051-27 Sponsor Protocol Number: PM/0041 Start Date*: 2016-09-22
    Sponsor Name:HAL Allergy B.V.
    Full Title: A randomized, double-blind, placebo-controlled (DBPC) parallel-group multi-centre study to assess the efficacy and safety of PURETHAL Mites subcutaneous immunotherapy (SCIT) in patients with allerg...
    Medical condition: Allergic rhinitis/rhinoconjunctivitis (ARC) caused by house dust mite (HDM) allergy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    20.0 100000004855 10001724 Allergic rhinitis (excl hay fever) LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed) HU (Completed) ES (Completed) BE (Completed) PT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 19:24:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA